Logo image of CASI

CASI PHARMACEUTICALS INC (CASI) Stock Fundamental Analysis

NASDAQ:CASI - Nasdaq - KYG1933S1012 - Common Stock - Currency: USD

1.63  +0.16 (+10.88%)

After market: 1.6 -0.03 (-1.84%)

Fundamental Rating

1

Overall CASI gets a fundamental rating of 1 out of 10. We evaluated CASI against 551 industry peers in the Biotechnology industry. CASI has a bad profitability rating. Also its financial health evaluation is rather negative. CASI is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year CASI has reported negative net income.
CASI had negative earnings in each of the past 5 years.
CASI had a negative operating cash flow in each of the past 5 years.
CASI Yearly Net Income VS EBIT VS OCF VS FCFCASI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M

1.2 Ratios

The Return On Assets of CASI (-99.16%) is worse than 75.86% of its industry peers.
Industry RankSector Rank
ROA -99.16%
ROE N/A
ROIC N/A
ROA(3y)-50.53%
ROA(5y)-43.18%
ROE(3y)-774.83%
ROE(5y)-485.42%
ROIC(3y)N/A
ROIC(5y)N/A
CASI Yearly ROA, ROE, ROICCASI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K -2K

1.3 Margins

The Gross Margin of CASI (56.62%) is better than 78.04% of its industry peers.
CASI's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for CASI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 56.62%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.45%
GM growth 5Y63.76%
CASI Yearly Profit, Operating, Gross MarginsCASI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5K -10K -15K

More info and screens

0

2. Health

2.1 Basic Checks

CASI does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CASI has more shares outstanding
Compared to 5 years ago, CASI has more shares outstanding
Compared to 1 year ago, CASI has a worse debt to assets ratio.
CASI Yearly Shares OutstandingCASI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
CASI Yearly Total Debt VS Total AssetsCASI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

CASI has an Altman-Z score of -26.39. This is a bad value and indicates that CASI is not financially healthy and even has some risk of bankruptcy.
CASI has a worse Altman-Z score (-26.39) than 87.84% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -26.39
ROIC/WACCN/A
WACC9.6%
CASI Yearly LT Debt VS Equity VS FCFCASI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

A Current Ratio of 0.81 indicates that CASI may have some problems paying its short term obligations.
The Current ratio of CASI (0.81) is worse than 90.20% of its industry peers.
A Quick Ratio of 0.68 indicates that CASI may have some problems paying its short term obligations.
The Quick ratio of CASI (0.68) is worse than 90.56% of its industry peers.
Industry RankSector Rank
Current Ratio 0.81
Quick Ratio 0.68
CASI Yearly Current Assets VS Current LiabilitesCASI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

4

3. Growth

3.1 Past

CASI shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -10.09%.
Looking at the last year, CASI shows a quite strong growth in Revenue. The Revenue has grown by 8.39% in the last year.
CASI shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 47.19% yearly.
EPS 1Y (TTM)-10.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%2.82%
Revenue 1Y (TTM)8.39%
Revenue growth 3Y-1.84%
Revenue growth 5Y47.19%
Sales Q2Q%83.04%

3.2 Future

Based on estimates for the next years, CASI will show a very strong growth in Earnings Per Share. The EPS will grow by 21.15% on average per year.
CASI is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -10.80% yearly.
EPS Next Y19.14%
EPS Next 2Y16.76%
EPS Next 3Y16.43%
EPS Next 5Y21.15%
Revenue Next Year-36.85%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-10.8%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
CASI Yearly Revenue VS EstimatesCASI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2019 2020 2021 2022 2023 2024 2025 2029 2030 2031 2032 20M 40M 60M
CASI Yearly EPS VS EstimatesCASI Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -2 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CASI. In the last year negative earnings were reported.
Also next year CASI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CASI Price Earnings VS Forward Price EarningsCASI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CASI Per share dataCASI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2

4.3 Compensation for Growth

CASI's earnings are expected to grow with 16.43% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.76%
EPS Next 3Y16.43%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CASI!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CASI PHARMACEUTICALS INC

NASDAQ:CASI (8/8/2025, 8:22:28 PM)

After market: 1.6 -0.03 (-1.84%)

1.63

+0.16 (+10.88%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-16 2025-05-16/bmo
Earnings (Next)08-14 2025-08-14
Inst Owners15.06%
Inst Owner ChangeN/A
Ins Owners20.4%
Ins Owner Change0%
Market Cap25.25M
Analysts82.86
Price Target4.08 (150.31%)
Short Float %0.37%
Short Ratio0.18
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0.05
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)38.69%
Min Revenue beat(2)0.29%
Max Revenue beat(2)77.09%
Revenue beat(4)3
Avg Revenue beat(4)33.24%
Min Revenue beat(4)-11.97%
Max Revenue beat(4)77.09%
Revenue beat(8)3
Avg Revenue beat(8)1.39%
Revenue beat(12)6
Avg Revenue beat(12)3.96%
Revenue beat(16)8
Avg Revenue beat(16)4.06%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-33.51%
Revenue NY rev (3m)-33.51%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.8
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.51
EYN/A
EPS(NY)-1.66
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS2.03
BVpS-0.52
TBVpS-0.54
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -99.16%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 56.62%
FCFM N/A
ROA(3y)-50.53%
ROA(5y)-43.18%
ROE(3y)-774.83%
ROE(5y)-485.42%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.45%
GM growth 5Y63.76%
F-ScoreN/A
Asset Turnover0.77
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.81
Quick Ratio 0.68
Altman-Z -26.39
F-ScoreN/A
WACC9.6%
ROIC/WACCN/A
Cap/Depr(3y)100.64%
Cap/Depr(5y)428.5%
Cap/Sales(3y)6.82%
Cap/Sales(5y)39.9%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-10.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%2.82%
EPS Next Y19.14%
EPS Next 2Y16.76%
EPS Next 3Y16.43%
EPS Next 5Y21.15%
Revenue 1Y (TTM)8.39%
Revenue growth 3Y-1.84%
Revenue growth 5Y47.19%
Sales Q2Q%83.04%
Revenue Next Year-36.85%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-10.8%
EBIT growth 1Y-30.11%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-32.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-46.36%
OCF growth 3YN/A
OCF growth 5YN/A